Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The world’s largest genetic study into depression has uncovered life-changing discoveries that will revolutionise treatments ...